5.39
0.23 (4.46%)
| Penutupan Terdahulu | 5.16 |
| Buka | 5.02 |
| Jumlah Dagangan | 1,187,457 |
| Purata Dagangan (3B) | 2,691,344 |
| Modal Pasaran | 803,411,136 |
| Harga / Buku (P/B) | 4.77 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Mar 2026 |
| EPS Cair (TTM) | -1.17 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.61% |
| Nisbah Semasa (MRQ) | 7.99 |
| Aliran Tunai Operasi (OCF TTM) | -139.79 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -71.03 M |
| Pulangan Atas Aset (ROA TTM) | -37.66% |
| Pulangan Atas Ekuiti (ROE TTM) | -66.13% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Annexon, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | -1.30 |
|
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.42% |
| % Dimiliki oleh Institusi | 103.25% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bellevue Group Ag | 31 Dec 2025 | 5,157,290 |
| Longaeva Partners L.P. | 31 Dec 2025 | 3,100,000 |
| Mak Capital One Llc | 31 Dec 2025 | 2,958,527 |
| Julat 52 Minggu | ||
| Median | 16.00 (196.85%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 23 Dec 2025 | 16.00 (196.85%) | Beli | 5.11 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ARTIS DEAN RICHARD | - | 5.52 | -5,894 | -32,535 |
| DANANBERG JAMIE | - | 5.52 | -5,820 | -32,126 |
| LEW JENNIFER | - | 5.52 | -5,565 | -30,719 |
| OVERDORF MICHAEL | - | 5.52 | -4,339 | -23,951 |
| YEDNOCK TED | - | 5.52 | -5,566 | -30,724 |
| Jumlah Keseluruhan Kuantiti Bersih | -27,184 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -150,056 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 5.52 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| YEDNOCK TED | Pegawai | 02 Mar 2026 | Jual (-) | 5,566 | 5.52 | 30,724 |
| LEW JENNIFER | Pegawai | 02 Mar 2026 | Jual (-) | 5,565 | 5.52 | 30,719 |
| OVERDORF MICHAEL | Pegawai | 02 Mar 2026 | Jual (-) | 4,339 | 5.52 | 23,951 |
| ARTIS DEAN RICHARD | Pegawai | 02 Mar 2026 | Jual (-) | 5,894 | 5.52 | 32,535 |
| DANANBERG JAMIE | Pegawai | 02 Mar 2026 | Jual (-) | 5,820 | 5.52 | 32,126 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Jan 2026 | Pengumuman | Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Pengumuman | Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 |
| 08 Jan 2026 | Pengumuman | Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome |
| 07 Jan 2026 | Pengumuman | Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 16 Dec 2025 | Pengumuman | Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |